Navigation Links
Introgen and Clinical Collaborators to Report New Results with,Advanced-Stage Cancer Therapies at Upcoming Medical Meetings

AUSTIN, Texas--(BUSINESS WIRE)--May 29, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) and the Company's clinical collaborators will report updated Phase 2 clinical trial results for its lead cancer therapy product candidates at the upcoming annual meetings of The American Society of Clinical Oncology (ASCO) in Chicago and the American Society of Gene Therapy (ASGT) in Seattle.

"We have a stronger than ever, advancing pipeline of first-in-class cancer therapies generating exciting data that could change the way cancer is treated and fulfill the promise of molecularly targeted cancer therapy," said Robert E. Sobol, M.D., senior vice president of Medical and Scientific Affairs at Introgen. "We have multiple Phase 3 programs either underway or planned with the goal of bringing these therapies to market to provide new treatments for widely underserved patient populations that are effective, generally well tolerated and can be easily combined and act synergistically with standard therapies by or before the end of this decade."

ASCO

-- Final results of a phase II trial of patients with extensive stage small cell lung cancer (ES-SCLC) immunized with wild type -p53 transduced dendritic cells after first-line chemotherapy, Abstract #3012: Poster presentation on Sun., June 3, from 2:00 - 6:00 p.m. in room S102a at McCormick Place, by lead author Alberto Chiappori, M.D., H. Lee Moffitt Cancer Center and Research Institute.

-- Tumor response criteria and biomarkers associated with increased survival following adenoviral p53 gene therapy (ADVEXIN) in patients with recurrent squamous cell carcinoma of the head and neck, Abstract #6057: Poster presentation on Mon., June 4, from 1:00 - 5:00 p.m. at McCormick Place by lead author John Nemunaitis, M.D., Mary Crowley Medical Research Center and poster presentation by Robert Sobol, M.D., Introgen Therapeutics, Inc.

ASGT

-- Role of the Immune Sy stem in Replicating Adenovirus Using a Permissive Immune Competent Syrian Hamster Model, William Wold, Ph.D., St. Louis University School of Medicine: Presentation on Thurs., May 31, from 9:30 - 11:30 a.m. at Washington State Convention Center during symposium titled "Cancer: Hot Topics in Cancer Gene Therapy"

-- MDA-7 (INGN-241) Kills Chemoresistant Cancer Cells and Restores Chemosensitivity to Cisplatin, Abstract #197: Presentation during "Cancer: Apoptosis and Suicide" poster session on Thurs., May 31, from 5:00 - 8:00 p.m. at Washington State Convention Center by Rajagopal Ramesh, Ph.D., M. D. Anderson Cancer Center

-- Effect of Pre-existing Anti-Adenovirus Immunity and Anti-Tumor Immunity on the Efficacy of Adenovirus Vectors in Immunocompetent Syrian Hamster Model, Abstract #668: Presentation during "Immune Responses to Adenoviral Vectors" poster session on Fri, June 1, from 5:15- 8:15 p.m. in Hall 4AB at Washington State Convention Center by Debanjan Dhar, St. Louis University School of Medicine

-- Anticancer Activity of Oncolytic Adenovirus Vector Armed with IFN-alpha and ADP is Enhanced by Pharmacologically-Controlled Expression of TRAIL, Abstract #588: Presentation during "Cancer Immunotherapy II" poster session on Fri., June 1, 2007 from 5:15 - 8:15 p.m. in Hall 4AB at Washington State Convention Center by Elena V. Shashkova, VirRx, Inc.

-- Clinical Experience with the mda-7/IL-24 Tumor Suppressor, Abstract # 380: Presentation during "Tumor Suppressor and Targeted Gene Therapy" poster session and oral presentation on Friday, June 1, 2007 at 8:45 a.m. at the Washington State Convention Center by Sunil Chada, Ph.D., Introgen Therapeutics, Inc.

About Introgen Therapeutics, Inc.

Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutic s, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.

Statements in this release that are not strictly historical may be "forward-looking" statements, including those relating to Introgen's future success with its ADVEXIN, INGN 241, and INGN 007 clinical development programs. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen's operations and business environment, including Introgen's stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen's product candidates, the ability to obtain the appropriate regulatory approvals, Introgen's patent protection and market acceptance, as well as other risks detailed from time to time in Introgen's filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.

Editor's Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen's Website at: www.introgen.com.

Contact

Introgen Therapeutics, Inc., Austin
C. Channing Burke, 512-708-9310, ext. 322
c.burke@introgen.com


'"/>




Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241 in Patients With Advanced Solid Tumors
3. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Genetic Analysis Systems Enter the Clinical Mainstream
7. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
8. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
9. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... --  Health 2.0 , the premiere showcase and catalyst ... " 10 Year Global Retrospective ", a platform to ... ten years.   --> ... served as the preeminent thought-leader in the health tech ... companies, innovators, and patient-activists through an array of events ...
(Date:2/11/2016)... , Feb. 11, 2016 AAIPharma ... provider of custom manufacturing and development services for ... sterile fill-finish capabilities and capacity in its ... in demand has driven several recent investments. ... it had one filling line with small-scale lyophilization. ...
(Date:2/11/2016)... ANKENY, Iowa , 11 de fevereiro de ... a inauguração de sua fábrica de soroalbumina bovina ... Nova Zelândia. A fábrica fica na Ilha Norte ... Loop "), desenvolvido e estabelecido na fábrica da ... Iowa . O projeto e instalação dos ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... Florida Hospital presents Heart Health Awareness night ... Louis Blues at the Amalie Arena. The puck drops at 6:00pm, but fans will ... MEGA Heart, prior to the game. The MEGA Heart will be located on Ford ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has been gearing up for their simultaneous grand openings in March. All seven ... now that you’re probably wondering, is reversing diabetes possible? According to this 2011 ...
(Date:2/11/2016)... Plantation, Fla. (PRWEB) , ... February 11, 2016 ... ... CareTRAK™, an unparalleled clinical decision support technology, with highly adaptable algorithms, has ... cases. When a patient has signs and symptoms consistent with Zikas and a ...
(Date:2/11/2016)... ... February 11, 2016 , ... Greenfield Insurance Group in ... to assist the people of their local community. The agency pledges to select ... leaders. Their hope is to bring awareness to important local causes with fundraising ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dickinson Insurance & Financial Services continues their ... fundraiser in support of a local boy named Barrett, who has been fighting ALL ... to, and rally support for, all local families dealing with childhood cancer. Information on ...
Breaking Medicine News(10 mins):